Quantum BioPharma board authorizes Class A multiple-voting share offering to lift control stake to 75.27%
QNTM•Director conflicts and abstentions
Directors held informal discussions excluding Zeeshan Saeed and Anthony Durkacz, and both abstained due to conflicts under the OBCA.
Board authorizes Class A share offering to restore voting control
Quantum BioPharma board authorizes Class A multiple-voting share offering to lift control stake to 75.27%.
- Board action on Oct. 29, 2025 set up an offering of Class A Multiple Voting Shares to restore voting control toward IPO levels.
- If fully subscribed, Class A voting rights rise to 75.27% from 46.52% following years of Class B Subordinate Voting Share issuances.
- Proceeds are earmarked for general working capital.
- The new Class A shares carry a four-month-and-one-day Canadian hold period.
